Depression Symptoms Treatment
Archive for the ‘Celexa (Citalopram)’ Category
Drug Approvals
(British Approved Name, rINN)
Synonyms: Citalopram; Citalopramum; Lu-10-171; Sitalopraami
BAN: Citalopram
INN: Citalopram [rINN (en)]
INN: Citalopram [rINN (es)]
INN: Citalopram [rINN (fr)]
INN: Citalopramum [rINN (la)]
INN: Циталопрам [rINN (ru)]
Chemical name: 1-(3-Dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
Molecular formula: C20H21FN2O =324.4
CAS: 59729-33-8
ATC code: N06AB04
Citalopram Hydrobromide
(British Approved Name Modified, rINNM)
Drug Nomenclature
Synonyms: Citalopram, hidrobromuro de; Lu-10-171B; Nitalapram Hydrobromide
BAN: Citalopram Hydrobromide [BANM]
USAN: Citalopram Hydrobromide
INN: Citalopram Hydrobromide [rINNM (en)]
INN: Hidrobromuro de citalopram [rINNM (es)]
INN: Citalopram, Bromhydrate de [rINNM (fr)]
INN: Citaloprami Hydrobromidum [rINNM (la)]
INN: Циталопрама Гидробромид [rINNM (ru)]
Molecular formula: C20H21FN2O,HBr =405.3
CAS: 59729-32-7
Pharmacopoeias. In US.
The United States Pharmacopeia 31, 2008 (Citalopram Hydrobromide). A white to almost white, crystalline powder. Freely soluble Read more [...]
Citalopram (Celexa, Forest Laboratories, Parke-Davis) has been approved by FDA for treatment of depression. A highly selective serotonin reuptake inhibitor, citalopram is the best-selling antidepressant in 13 countries, including eight in Europe. Citalopram has proven effective in treatment of depression in clinical trials involving 23,000 patients and has been used in some 8 million patients in 64 countries where the drug is already approved. Two, six-month, double-blind, placebo-controlled studies indicated that citalopram is significantly more effective than placebo in preventing relapse of depression.
Side effects include nausea, dry mouth, and sleepiness. As with all SSRIs, citalopram should not be taken with monoamine oxidase inhibitors.
Concomitant administration of imipramine, lithium, and levomepromazine had no effect on Tmax values of citalopram or its metabolites. In contrast, cimetidine caused a statistically significant decrease in the Tmax value of citalopram and an increase in that of DCT.
In an evaluation of the effects of psychotropic drugs on serum citalopram concentrations in psychiatric patients, individual neuroleptics (perphenazine, thioridazine, periciazin, chlorpromazine, haloperidol, zuclopenthixol, and levomepromazine) had no effect on serum citalopram or its demethyl derivative. Only alprazolam among the benzodiazepines tested (including oxazepam, diazepam, temazepam, clonazepam, lorazepam, chlorazepam, and chlordiazepoxide) had any effect on citalopram and DCT concentrations, increasing them by 20% and 48%, respectively. Among the antidepressants administered concomitantly with citalopram, clomipramine exerted the most effect, increasing citalopram and DCT concentrations by 94% and 250%, respectively.
Concomitant administration of cimetidine caused a significant increase in the average steady-state levels Read more [...]
Directions for use conveyed in the sponsor’s proposed labeling are as follows:
Citalopram should be administered at a dose of 20 mg once daily. Clinical trials demonstrating antidepressant effectiveness studied the recommended therapeutic dose range of 20-60 mg/day. Patients not responding to 20 mg may benefit from dose increases, in 20 mg/day increments, up to a maximum of 60 mg/day. Dose changes should occur at intervals of at least one week.
Citalopram should be administered once daily, in the morning or evening, with or without food.
In elderly patients, dosage should not exceed 40 mg/day. In patients with hepatic impairment, dosage should not exceed 40 mg/day. No dosage adjustment is necessary for patients with mild or moderate renal impairment, but should be used with caution in patients with severe renal impairment.